Neurology Central

AAIC 2018: Day 4 Update


Video highlight

Catch up on our daily update from Day 1 here.

Catch up on our daily update from Day 2 here

Catch up on our daily update from Day 3 here

Today’s news

AAIC 2018: Could intensive blood pressure control reduce the risk of MCI and dementia?

Pick of the posters

  • Gatt A, Whitfield DR, Chambers D et alA ‘triage’ system for identifying candidate compounds for repurposing as potential therapeutics for AD. The aim of this study was to validate the use of the connectivity map project (CMAP) bioinformatic approach to identify potential therapeutic compounds for clinical use. The researchers anticipate that this approach, which integrates in silico, in vitro and in vivo findings could identify compounds that may be repurposed to serve as Alzheimer’s therapeutics.
  • Lynch SY, Kaplow J, Zhao J, Dhadda S, Luthman J, Albala B. Elenbecestat, a BACE inhibitor: results from a Phase II study in subjects with mild cognitive impairment and mild-to-moderate dementia due to Alzheimer’s disease. Phase I clinical studies of elenbecestat have demonstrated robust dose- and exposure-related effects of elenbecestat on plasma amyloid beta (Aβ)1-x and CSF Aβ(1-x), Aβ40, Aβ42, and BACE1 activity for doses ranging from 25 to 400 mg in healthy elderly subjects. This Phase II study was an 18-month, placebo-controlled study investigating the safety and efficacy of elenbecestat in MCI-to-moderate Alzheimer’s patients. Their conclusions revealed that elenbecestat was generally well tolerated with no unexpected safety concerns evident in the study.
  • Day GS, Amtashar F, Yarbrough ML et al. Quantifying CSF biofluid biomarkers of neuronal injury, neuroinflammation and neurotransmission in antibody mediated encephalitis. The objective of this study was to measure CSF biomarkers of neuronal injury, neuroinflammation and synaptic function in antibody mediated encephalitides. They summarized that neuronal integrity was acutely maintained in antibody mediated encephalitides patients and that neuroinflammatory markers were increased, whilst markers of synaptic function were decreased. In conclusion, they stated that biofluid biomarkers validated in patients with neurodegenerative diseases can inform antibody mediated encephalitides pathogenesis and may predict outcomes in recovering patients.

Picture of the day

See you next year at AAIC in Los Angeles! 

Today at our booth

Today was our last day exhibiting at AAIC 2018 and it’s been a fantastic conference overall – we’re already excited for next year’s AAIC 2019 conference! If you’re an early career researcher and are also attending, do let us know if you’d be interested in publishing a conference report for us. You can contact our Editor via email by clicking here.

Remember to sign up for Neuro Central, or follow our Twitter updates @Neuro_Central

Best of social media #AAIC18